Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
<p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most...
Main Authors: | Bacchiocchi Antonella, Cheng Elaine, Ariyan Stephan, Pavlick Anna C, Sznol Mario, Rubinstein Jill C, Kluger Harriet M, Narayan Deepak, Halaban Ruth |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-07-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/8/1/67 |
Similar Items
-
Differential sensitivity of melanoma cell lines with <it>BRAF</it><sup><it>V600E </it></sup>mutation to the specific Raf inhibitor PLX4032
by: Kehoe Sarah M, et al.
Published: (2010-04-01) -
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
by: William D. Tap, et al.
Published: (2010-08-01) -
Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function
by: Martin Michaelis, et al.
Published: (2014-04-01) -
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
by: Honglai Zhang, et al.
Published: (2018-10-01) -
The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01)